B. Tessoulin, M. Eveillard, A. Lok, D. Chiron, P. Moreau et al., p53 dysregulation in B-cell malignancies: more than a single gene in the pathway to hell, Blood Rev, vol.31, pp.251-260, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01493742

C. W. Eskelund, C. Dahl, J. W. Hansen, M. Westman, A. Kolstad et al., TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy, Blood, vol.130, pp.1903-1913, 2017.

B. A. Walker, K. Mavrommatis, C. P. Wardell, T. C. Ashby, M. Bauer et al., A high-risk, double-Hit, group of newly diagnosed myeloma identified by genomic analysis, Leukemia, 2018.

J. Xu, J. Qian, Y. Hu, J. Wang, X. Zhou et al., Heterogeneity of Li-Fraumeni syndrome links to unequal gain-of-function effects of p53 mutations, Sci Rep, vol.4, p.4223, 2014.

W. Hanel, N. Marchenko, S. Xu, S. X. Yu, W. Weng et al., Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis, Cell Death Differ, vol.20, pp.898-909, 2013.

V. Bykov, S. E. Eriksson, J. Bianchi, and K. G. Wiman, Targeting mutant p53 for efficient cancer therapy, Nat Rev Cancer, vol.18, pp.89-102, 2018.

Q. Zhang, J. Bergman, K. G. Wiman, and V. Bykov, Role of Thiol Reactivity for Targeting Mutant p53, Cell Chem Biol, vol.25, 2018.

Q. Zhang, V. Bykov, K. G. Wiman, and J. Zawacka-pankau, APR-246 reactivates mutant p53 by targeting cysteines 124 and 277, Cell Death Dis, vol.9, p.439, 2018.
DOI : 10.1101/214049

URL : https://www.biorxiv.org/content/biorxiv/early/2017/11/05/214049.full.pdf

S. Surget, G. Descamps, C. Brosseau, V. Normant, S. Maiga et al., Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway, BMC Cancer, vol.14, p.437, 2014.

B. Tessoulin, G. Descamps, P. Moreau, S. Maiga, L. Lode et al., PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance, Blood, vol.124, pp.1626-1662, 2014.

M. Wanzel, J. B. Vischedyk, M. P. Gittler, N. Gremke, J. R. Seiz et al., CRISPR-Cas9-based target validation for p53-reactivating model compounds, Nat Chem Biol, vol.12, pp.22-30, 2016.

J. M. Lambert, P. Gorzov, D. B. Veprintsev, M. Soderqvist, D. Segerback et al., PRIMA-1 reactivates mutant p53 by covalent binding to the core domain, Cancer Cell, vol.15, pp.376-88, 2009.

D. S. Liu, C. P. Duong, S. Haupt, K. G. Montgomery, C. M. House et al., Inhibiting the system xC(-)/glutathione axis selectively targets cancers with mutant-p53 accumulation, Nat Commun, vol.8, p.14844, 2017.

X. Peng, M. Q. Zhang, F. Conserva, G. Hosny, G. Selivanova et al., APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase, Cell Death Dis, vol.4, p.881, 2013.

S. Maiga, C. Brosseau, G. Descamps, C. Dousset, P. Gomez-bougie et al., A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines, Cytometry A, vol.87, pp.285-293, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-02100586

J. Moreaux, B. Klein, R. Bataille, G. Descamps, S. Maiga et al., A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines, Haematologica, vol.96, pp.574-82, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00550232

B. Tessoulin, A. Moreau-aubry, G. Descamps, P. Gomez-bougie, M. S. Gaignard et al., Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways, J Hematol Oncol, vol.11, p.137, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-01958772

L. Lode, M. Eveillard, V. Trichet, T. Soussi, S. Wuilleme et al., Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma, Haematologica, vol.95, pp.1973-1979, 2010.

A. Lok, G. Descamps, B. Tessoulin, D. Chiron, M. Eveillard et al., p53 regulates CD46 expression and measles virus infection in myeloma cells, Blood Adv, vol.2, pp.3492-505, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-01957487

S. Surget, D. Chiron, P. Gomez-bougie, G. Descamps, E. Menoret et al., Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells, Cancer Res, vol.72, pp.4562-73, 2012.

P. Gomez-bougie, M. S. Tessoulin, B. Bourcier, J. Bonnet, A. Rodriguez et al., BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment, Blood, vol.132, pp.2656-69, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-01900681

G. X. Hou, P. P. Liu, S. Zhang, M. Yang, J. Liao et al., Elimination of stemlike cancer cell side-population by auranofin through modulation of ROS and glycolysis, Cell Death Dis, vol.9, p.89, 2018.

C. Dousset, S. Maiga, P. Gomez-bougie, L. Coq, J. Touzeau et al., BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma, Br J Haematol, vol.179, pp.684-692, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01353369

J. Hu, H. Zhang, M. Cao, L. Wang, S. Wu et al., Auranofin Enhances Ibrutinib's Anticancer Activity in EGFR-Mutant Lung Adenocarcinoma, Mol Cancer Ther, vol.17, pp.2156-63, 2018.
DOI : 10.1158/1535-7163.mct-17-1173